Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, Robert W. Baird Analyst Says
Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) had its price objective hoisted by analysts at Robert W. Baird from $32.00 to $40.00 in a report released on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 63.87% from the company’s current […]
More Stories
Natixis Advisors LLC Acquires 288,968 Shares of Eni S.p.A. (NYSE:E)
Natixis Advisors LLC raised its stake in Eni S.p.A. (NYSE:E – Free Report) by 12.8% during the third quarter, HoldingsChannel.com...
1,100 Shares in Edwards Lifesciences Co. (NYSE:EW) Acquired by AM Squared Ltd
AM Squared Ltd bought a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the 3rd quarter, according...
KCM Investment Advisors LLC Has $340,000 Position in Norfolk Southern Co. (NYSE:NSC)
KCM Investment Advisors LLC decreased its holdings in shares of Norfolk Southern Co. (NYSE:NSC – Free Report) by 6.8% during...
Claro Advisors LLC Has $13.18 Million Holdings in iShares Russell 1000 Value ETF (NYSEARCA:IWD)
Claro Advisors LLC boosted its position in shares of iShares Russell 1000 Value ETF (NYSEARCA:IWD – Free Report) by 9.0%...
Mizuho Markets Americas LLC Sells 5,531 Shares of Kimberly-Clark Co. (NYSE:KMB)
Mizuho Markets Americas LLC reduced its stake in Kimberly-Clark Co. (NYSE:KMB – Free Report) by 12.1% during the third quarter,...
Kentucky Retirement Systems Decreases Stake in Kimberly-Clark Co. (NYSE:KMB)
Kentucky Retirement Systems cut its stake in shares of Kimberly-Clark Co. (NYSE:KMB – Free Report) by 7.5% in the third...